Ratings MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
4.39 ^USD	+0.23%		+3.78%	+20.60%

30/04	MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	CI
29/04	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	MT

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The firm trades with high earnings multiples: 33.26 times its 2024 earnings per share.
With an enterprise value anticipated at 3.62 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MANNKIND CORPORATION	+20.60%	1.19B	C+
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B	B+
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B	B+
ARGENX SE	+4.40%	22.94B	B
BIONTECH SE	-12.15%	22.34B	B+
GENMAB A/S	-4.36%	19.25B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.08B	A-
BEIGENE, LTD.	-10.04%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B	C+
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes